BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · $80,000.00 income · posted Jan 13, 2026

Lobbying activity 2

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement DTC Advertising

Tariff (miscellaneous tariff bills)

Reciprocal tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.